Showing results (91-100 of 4,234) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|August 3, 2021
High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilegeCasey R Ager, Akash Boda, Kimal Rajapakshe, et al.Journal for Immunotherapy of Cancer|August 23, 2022
Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016Tamara A Sussman, Rebecca Knackstedt, Wei Wei, et al.Journal for Immunotherapy of Cancer|August 24, 2022
Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissectionZeynep Eroglu, Kristy K Broman, John F Thompson, et al.Journal for Immunotherapy of Cancer|August 24, 2022
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort studyJi Hyun Lee, Sujin Hyung, Jeeyun Lee, et al.Journal for Immunotherapy of Cancer|August 28, 2021
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)Russell K Pachynski, Chihiro Morishima, Russell Szmulewitz, et al.Journal for Immunotherapy of Cancer|November 18, 2021
Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoidsQingda Meng, Shanshan Xie, G Kenneth Gray, et al.Journal for Immunotherapy of Cancer|November 18, 2021
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational studyFangwen Zou, David Faleck, Anusha Thomas, et al.Journal for Immunotherapy of Cancer|November 19, 2021
A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanomaAndreas Stefan Brendlin, Felix Peisen, Haidara Almansour, et al.Journal for Immunotherapy of Cancer|January 14, 2022
Large-scale manufacturing and characterization of CMV-CD19CAR T cellsXiuli Wang, Ryan Urak, Miriam Walter, et al.Journal for Immunotherapy of Cancer|January 18, 2022
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancerKazuki Nishimura, Kyosuke Nishio, Kensuke Hirosuna, et al.Pageof 424